Navigation Links
Molecular Breast Imaging Proves Cost-Effective for Presurgical Planning in Patients with Breast Cancer
Date:12/1/2008

CHICAGO, Dec. 1 /PRNewswire/ -- Breast-Specific Gamma Imaging (BSGI), a molecular breast imaging technique that is substantially less expensive than breast magnetic resonance imaging (MRI) with comparable sensitivity for detecting breast carcinoma when used in presurgical planning for patients with known cancer diagnoses, according to findings presented today at the annual meeting of the Radiological Society of North America (RSNA).

"According to the national Medicare average, BSGI costs $219.43 compared to $994.43 for breast MRI. Since BSGI has some advantages over MRI, including higher patient tolerance and significant cost savings, BSGI should be considered an alternative for preoperative planning in patients with breast carcinoma," said Dr. Margaret Bertrand, Director of Breast Imaging at Solis Bertrand Breast Center in Greensboro, N.C.

In this study, BSGI was performed prior to needle biopsy on 63 patients with 64 breast malignancies who subsequently had a post-biopsy, preoperative breast MRI for surgical planning in accordance with the ACS guidelines. Of the 64 malignancies, BSGI and MRI were positive in 61 and 62 lesions, respectively. BSGI and MRI were comparable in sensitivity for breast carcinoma, 95 percent and 97 percent respectively. Unlike MRI, BSGI was tolerated by all patients.

BSGI for the study was conducted using a Dilon 6800 Gamma Camera, a high-resolution, small field-of-view gamma camera, optimized to perform BSGI. BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than the normal surrounding tissue and generally appear as "hot spots" on the BSGI image.

About Dilon Technologies

Dilon Technologies Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston.

For more information on Dilon Technologies please visit http://www.dilon.com.


'/>"/>
SOURCE Dilon Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Molecular Breast Imaging Performs Better Than Ultrasound in Patients With Mammographic Abnormalities
2. Molecular partnership controls daily rhythms, body metabolism
3. Molecular Switch in Brain May End Smokers Cravings
4. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
5. Four of Molecular Medicine's Thought Leaders will Keynote at Cambridge Healthtech Institute's Molecular Medicine Tri-Conference
6. Thinking Systems Corporation Announces Integration of Its ThinkingPACS(TM) for Molecular Imaging Into Fujifilms Synapse(R) PACS
7. Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
8. Penn scientists map molecular regulation of fat-cell genetics
9. SNM to showcase the latest research in molecular imaging and nuclear medicine
10. Transplantation: molecular miscegenation blurs the boundary between self and non-self
11. Battelle to Perform Verification Studies of IntelligentMDxs Proprietary Molecular Diagnostic Assay Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... agile ecosystem and domain expertise for sponsors and CROs to speed clinical ... supply management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and funding ... randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients ... complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving ... and head shops –can’t help but be heartened by the industry’s current surge. But ... aptly described as “skunk smell.” At last they can simply, safely and effectively ...
(Date:4/25/2017)... ... 25, 2017 , ... Vetoquinol USA® , a world-class ... part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in ... immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
(Date:4/18/2017)... 2017  Cardinal Health (NYSE: CAH ) ... earnings per share (EPS) guidance and providing a preliminary ... conjunction with this morning,s announcement of the planned acquisition ... Insufficiency businesses. Cardinal Health now believes that ... at the bottom of its previous guidance range of ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology: